Retatrutide 10mg Triple-Agonist Metabolic Peptide | Advanced Metabolic Research
Retatrutide 10mg Triple-Agonist Metabolic Peptide | Advanced Metabolic Research
Retatrutide 10mg Triple-Agonist Metabolic Peptide | Advanced Metabolic Research
Overview Retatrutide is a next-generation synthetic peptide engineered as a triple receptor agonist, simultaneously targeting the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. The 10mg presentation is developed for advanced research into metabolic regulation, energy expenditure, and adipose tissue biology — positioned at the cutting edge of incretin-class peptide science.
Mechanism of Interest Retatrutide represents the evolution of incretin research beyond single- and dual-agonist models (such as semaglutide and tirzepatide). By engaging three distinct metabolic receptors in concert, it has become a focal point in research investigating energy balance, lipolysis, glucose handling, hepatic metabolism, and central appetite regulation. The triple-agonist profile is of particular interest in studies exploring synergistic effects on body composition, metabolic flexibility, and obesity-related pathways.
Product Specifications
- Product Name: Retatrutide 10mg
- Catalogue Reference: RETA10-024
- Class: GLP-1 / GIP / Glucagon Triple Agonist
- Purity: ≥98% (HPLC verified)
- Presentation: Lyophilised solid
- Storage: -20°C
Research Applications Retatrutide is utilised across metabolic, endocrinology, and obesity research — particularly in studies investigating adiposity reduction, insulin sensitivity, hepatic lipid metabolism, energy expenditure, appetite signalling, and cardiometabolic markers. Its triple-receptor engagement makes it one of the most advanced research tools available for investigating multi-pathway metabolic modulation.
Comparative Research Context Retatrutide is frequently studied alongside semaglutide (GLP-1 mono-agonist) and tirzepatide (GLP-1/GIP dual-agonist) in comparative research models, where its additional glucagon receptor activity is explored as a contributor to enhanced energy expenditure and hepatic effects — distinguishing it from earlier-generation incretin peptides.
Quality & Handling Synthesised under controlled laboratory conditions and supplied as a lyophilised solid for maximum stability. Reconstitution with appropriate bacteriostatic solution is required prior to use in any research model. Every batch is subjected to rigorous quality control to ensure purity, structural integrity, and batch-to-batch consistency.
Compliance Statement All Asclepius peptide products are supplied strictly for laboratory research purposes. They are not intended for human consumption, diagnosis, treatment, or therapeutic use. Enquiries relating to human application cannot be supported.
Order with Confidence Asclepius peptides are sourced, tested, and dispatched to a clinical standard — built for researchers and practitioners who refuse to compromise on integrity, purity, or precision.
For technical specifications, certificates of analysis, or research support, our team is available to assist.